Trial Information
A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Inclusion Criteria:
- Histologically or cytologically confirmed advanced squamous NSCLC
- Measurable disease as defined per modified RECIST criteria
- ECOG performance status of 0 or 1
- ≥18 years old
- Adequate glycemic function, for subjects with known diabetes
Exclusion Criteria:
- Untreated or symptomatic central nervous system (CNS) metastases
- Prior anti-cancer therapy as follows: Any prior chemotherapy for squamous NSCLC; Any
prior adjuvant or neoadjuvant chemotherapy for squamous NSCLC; Any prior
chemoradiation for squamous NSCLC; Central (chest) radiation therapy ≤ 28 days prior
to enrollment, radiation therapy for peripheral lesions≤14 days prior to enrollment
for squamous NSCLC
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Part 1: The incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicities
Outcome Time Frame:
Part 1 Only
Safety Issue:
Yes
Principal Investigator
MD
Investigator Role:
Study Director
Investigator Affiliation:
Amgen
Authority:
United States: Food and Drug Administration
Study ID:
20080257
NCT ID:
NCT00807612
Start Date:
January 2009
Completion Date:
August 2010
Related Keywords:
- Advanced Squamous Non-Small Cell Lung Cancer
- AMG 479
- IGF-1R
- Apoptosis
- Monoclonal Antibody
- Advanced Squamous Non-Small Cell Lung Cancer
- antibody 1st-line
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
Research Site |
Bentonville, Arkansas |
Research Site |
Bloomington, Indiana |
Research Site |
Ashland, Kentucky |
Research Site |
Branson, Missouri |
Research Site |
Asheville, North Carolina |
Research Site |
Allentown, Pennsylvania |
Research Site |
Charleston, South Carolina |
Research Site |
Chattanooga, Tennessee |
Research Site |
Appleton, Wisconsin |